Dec 23, 2022, This Week in Cardiology Podcast

12/23/22 • 27 min

The top ten stories of the year plus a few honorary mentions. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I Annual Wrap Ups on Medscape

Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607

2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505

Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647

II REVIVED BCIS2

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606

PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862

PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853

III GUIDE HF

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2

CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278

GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390

IV DECAAF II

Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation The DECAAF II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2793452

DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469

V DANCAVAS

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681

DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854

Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153

DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632

VI SODIUM HF

Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5

Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482

Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697

SODIUM-HF Simplifies Message to Patients on Diet https://www.medscape.com/viewarticle/971547

VII STRONG-HF

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1

Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870

STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

VIII Health Insurance Access

Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://doi.org/10.1001/jamacardio.2022.1282

Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

I Annual Wrap Ups on Medscape

Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607

2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505

Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647

II REVIVED BCIS2

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606

PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862

PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853

III GUIDE HF

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2

CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278

GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390

IV DECAAF II

DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469

V DANCAVAS

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681

DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854

Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153

DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632

VI SODIUM HF

Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5

Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482

Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697

SODIUM-HF Simplifies Message to Patients on Diet https://www.medscape.com/viewarticle/971547

VII STRONG-HF

Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870

STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

VIII Health Insurance Access

Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://doi.org/10.1001/jamacardio.2022.1282

Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Previous Episode

Dec 16, 2022 This Week in Cardiology Podcast

BP control over the long term, omecamtiv mecarbil, incentives and Goodhart’s law, and open science are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. Long-Term BP Control

Final SPRINT Data Confirm Lower BP Is Better https://www.medscape.com/viewarticle/951572

Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://jamanetwork.com/journals/jamacardiology/fullarticle/2797064

Let's Not SPRINT to Judgment About New Blood Pressure Goals https://www.acpjournals.org/doi/full/10.7326/M15-3123

Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle? https://doi.org/10.1016/j.amjmed.2016.04.022

II. Omecamtiv Mecarbil

FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure https://www.medscape.com/viewarticle/985593

Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF https://www.medscape.com/viewarticle/978355

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction https://jamanetwork.com/journals/jama/fullarticle/2794362

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://doi.org/10.1093/eurheartj/ehac293

III. Measuring Quality of Care

MIPS Quality Scores Don't Reflect Quality of Care: Study https://www.medscape.com/viewarticle/985396

Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes https://jamanetwork.com/journals/jama/article-abstract/2799153

Pay for Performance When Slogans Overtake Science in Health Policy https://jamanetwork.com/journals/jama/fullarticle/2799177

Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law

IV. Open Science

Radial Artery Outlasts SVG as Second CABG Conduit, Cuts 5-Year Clinical Risk https://www.medscape.com/viewarticle/896122

Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results https://doi.org/10.1177/2515245917747646

Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting https://academic.oup.com/ejcts/article/62/1/ezac345/6604735?login=false

Do all roads lead to Rome? Critical reassessment of the individual patient meta-analysis on bypass grafts by Gaudino et al. https://doi.org/10.1093/ejcts/ezac564

Editorial: Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting: Different conduits or different trials? https://doi.org/10.1093/ejcts/ezac562

Features

Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Next Episode

Jan 6 2023 This Week in Cardiology

Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Damar Hamlin

Five Thoughts on the Damar Hamlin Collapse

https://www.medscape.com/viewarticle/986550

II. Semaglutide and Obesity in Adolescents

FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up

https://www.medscape.com/viewarticle/986403

• Once-Weekly Semaglutide in Adolescents with Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2208601

III. Open Data and PCSK9 inhibitors

Evolocumab Added to Statins Cuts CV Events in FOURIER Trial

https://www.medscape.com/viewarticle/877348

• Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

https://bmjopen.bmj.com/content/12/12/e060172

• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

https://www.nejm.org/doi/full/10.1056/nejmoa1615664

• PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction https://pubmed.ncbi.nlm.nih.gov/34252181/

• Bendary Tweet https://twitter.com/DrBendary/status/1609849852979986432?s=20&t=FDDhGIofS_HQ4jxf8aHwBA

IV. Open Data and TAVI vs SAVR Trials

Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799937

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]